Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Harmony Biosciences Holdings Inc maintains a gross margin of 71.88%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 15.82%, while the net margin is 9.22%. These profitability ratios, combined with a Return on Equity (ROE) of 20.75%, provide a clear picture of how effectively HRMY converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, HRMY competes directly with industry leaders such as ORKA and AMLX. With a market capitalization of $1.64B, it holds a leading position in the sector. When comparing efficiency, HRMY's gross margin of 71.88% stands against ORKA's N/A and AMLX's N/A. Such benchmarking helps identify whether Harmony Biosciences Holdings Inc is trading at a premium or discount relative to its financial performance.
